Arzneimittelforschung 2012; 62(03): 149-156
DOI: 10.1055/s-0031-1299695
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Synthesis, Anticancer Activity and Radiosensitizing Evaluation of Some New 2-Pyridone Derivatives

M. S. El-Said
1   Medicinal, Aromatic and Poisonous Plants Research Center (MAPPRC), College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
M. G. El-Gazzar
2   Department of Drug Radiation Research, National Center for Radiation Research and Technology, Nasr City, Cairo, Egypt
M. S. Al-Dosari
3   Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
M. M. Ghorab
1   Medicinal, Aromatic and Poisonous Plants Research Center (MAPPRC), College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
› Author Affiliations
Further Information

Publication History

received 17 November 2011

accepted 07 December 2011

Publication Date:
23 January 2012 (online)


Based on the reported anticancer activity of 2-pyridone, a new series of 6-amino-5-cyano-1-(3-ethylphenyl)-2-oxo-4-substituted-1,2-dihydropyridine-3-carbo-nitriles 4a-p were synthesized and tested for in-vitro anticancer activity against Ehrlich Ascites Carcinoma (EAC) cell line and liver human tumor cell line (HEPG2). Radiosensitizing activity was also evaluated. The starting material 2-cyano-N-(3-ethylphenyl)-acetamide 3 was obtained via reaction of 3-ethyl aniline 1 with ethyl cyanoacetate under condition of fusion. Upon treatment of compound 3 with aromatic aldehyde and malononitrile in the presence of catalytic amount of piperidine yielded the corresponding 1,2-dihydropyridine derivative 4a-p. Also chromenes 5 and 6 were obtained in good yield via reaction of compound 3 with salicyladehyde under different condition. The chromene derivatives 5 and 6 were further reacted with malononitrile in NH4OAc, afford the corresponding chromenopyridones 7 and 8. The structures of the synthesized compounds 3–8 were confirmed by analytical and spectral data. Compounds 4d, 4e, 5 and 6 showed higher anticancer activity against EAC cell line with IC50 values (75.32, 20.77, 73.1 and 67.05 µM) compared to doxorubicin as positive control with IC50 value (68.13 µM), moreover, these compounds showed potent activity on HEPG2 cell line with IC50 values (26.5, 19.2, 39.3, 44.9 µM), respectively, compared to doxorubicin (CAS 29042-30-6) (38.46 µM) and their activity increased synergistically when combined with γ-radiation.

  • References

  • 1 Abadi AH, Ibrahim TM, Abouzid KM et al. Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors. Bioorg Med Chem 2009; 17: 5974-5982
  • 2 Cheney IW, Yan S, Appleby T et al. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2007; 17: 1679-1683
  • 3 Wendt MD, Sun C, Kunzer A et al. Discovery of a novel small molecule binding site of human survivin. Bioorg Med Chem Lett 2007; 17: 3122-3129
  • 4 Aqui NA, Vonderheide RH. Survivin as a universal tumor antigen for novel cancer immunotherapy: functions of a killer clone. Cancer Biol Ther 2008; 7: 1888-1889
  • 5 Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921
  • 6 Gary P, Soh JW, Mao Y et al. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res 2000; 6: 4136-4141
  • 7 Cheng J, Grande JP. Cyclic Nucleotide Phosphodiesterase (PDE) Inhibitors: Novel Therapeutic Agents for Progressive Renal Disease. Exp Biol Med. 2007. 232. 38-51
  • 8 Murata T, Shimizu K, Narita M et al. Characterization of phosphodiesterase 3 in human malignant melanoma cell line. Anticancer Res 2002; 22: 3171-3174
  • 9 Murata T, Sugatani T, Shimizu K et al. Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular gland. Anticancer Drugs 2001; 12: 79-83
  • 10 Moon E, Lee R, Near R et al. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. Clin Cancer Res 2002; 8: 589-595
  • 11 Ghorab MM, Ragab FA, Hamed MM. Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety. Eur J Med Chem 2009; 44: 4211-4217
  • 12 Al-Said MS, Ghorab MM, Al-qasoumi SI et al. Synthesis and in vitro anticancer screening of some novel 4-[2-amino-3-cyano-4-substituted-5,6,7,8-tetrahydroquinolin-1-(4H)-yl]benzenesulfonamides. Eur J Med Chem 2010; 45: 3011-3018
  • 13 Al-qasoumi SI, Al-Taweel AM, Alafeey AM et al. Synthesis and biological evaluation of 2-amino-7,7-dimethyl 4-substituted-5-oxo-1-(3,4,5-trimethoxy)-1,4,5,6,7,8-hexahydro-quinoline-3-carbonitrile derivatives as potential cytotoxic agents. Bioorg Med Chem Lett 2009; 19: 6939-6942
  • 14 Ghorab MM, Ragab FA, Al-qasoumi SI et al. Synthesis of some new pyrazolo[3,4-d]pyrimidine derivatives of expected anticancer and radioprotective activity. Eur J Med Chem 2010; 45: 171-178
  • 15 Al-gasouni SI, Al-Taweel AM, Al-afeefy AM et al. Novel quinolines and pyrimido[4,5-b]quinolines bearing biologically active sulfonamide moiety as a new class of antitumor agents. Eur J Med Chem 2010; 45: 738-744
  • 16 Al-qasoumi SI, Al-Taweel AM, Alafeefy AM et al. Discovering some novel tetrahydroquinoline derivatives bearing the biologically active sulfonamide moiety as a new class of antitumor agents. Eur J Med Chem 2010; 45: 1849-1853
  • 17 Devi PU, Solomon FE, Sharada AC. Plumbagin, a plant naphthoquinone with antitumor and radiomodifying properties. Pharm Biol 1999; 37 (03) 231-236
  • 18 Brusick DJ. Cytogenetic Assays, Aberrations, and SCE Techniques in Carcinogenesis and Mutagenesis Testing. Human Press Inc.; Clifton, New Yersey: 1984. pp 265-276
  • 19 Skehan P, Storeng R, Scudiero D et al. New calorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112
  • 20 Nishimura Y. Rationale for chemoradiotherapy. Int J clin Oncol 2004; 9: 414-420